Boston Scientificvs.ResMed
BSX vs RMD · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Boston Scientific is about 1.9× larger than ResMed by market cap; Boston Scientific trades at the lower P/E (16.5 vs 20.7); year to date, ResMed leads (−6.2% vs −56.4%).
Side by side
| BSX | RMD | |
|---|---|---|
| Market cap | $60.7B | $31.5B |
| Price | $42.04 | $226.73 |
| Today | +1.1% | +0.3% |
| Return YTD | −56.4% | −6.2% |
| Return 1Y | −56.6% | −20.2% |
| Since June 26, 2026 | −5.0% | +13.2% |
| P/E | 16.5 | 20.7 |
| P/S | 2.9 | 5.6 |
| P/B | 2.4 | 4.8 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Boston ScientificBSX
Cardiology drives the growth, particularly electrophysiology, where Farapulse sits, and structural heart treatment. Endoscopy and urology cover the rest of the range.
Full BSX profile →ResMedRMD
CPAP machines and masks for sleep apnea, sold with cloud software, next to a wider respiratory equipment range.
Full RMD profile →More BSX & RMD comparisons
Other head-to-heads in the Medtech & devices segment.